Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest update is out from Organon ( (OGN) ).
Organon & Co. announced that the FDA has extended the review date for VTAMA® cream, used for treating atopic dermatitis, to March 12, 2025, without raising safety concerns. This extension impacts the company’s financial outlook for 2025, with expected revenue contributions and potential effects on earnings. Organon remains confident in the cream’s efficacy and is committed to providing the FDA with necessary information for approval.
See more data about OGN stock on TipRanks’ Stock Analysis page.
